Monopar Therapeutics
Monopar Therapeutics Inc. (Nasdaq: MNPR) is a clinical-stage biopharmaceutical company developing treatments for Wilson disease and radiopharmaceutical imaging agents and therapies for oncology. Its Wilson disease candidate, ALXN1840, is an investigational once-daily oral medicine licensed worldwide from Alexion for… From the company’s description.
In fiscal 2025, Monopar Therapeutics reported a net loss of $13.72M. Operations used $12.20M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Monopar Therapeutics does
In the company’s own words
Monopar Therapeutics Inc. (Nasdaq: MNPR) is a clinical-stage biopharmaceutical company developing treatments for Wilson disease and radiopharmaceutical imaging agents and therapies for oncology. Its Wilson disease candidate, ALXN1840, is an investigational once-daily oral medicine licensed worldwide from Alexion for development and commercialization. Its oncology programs use the MNPR-101 antibody to target cancers expressing uPAR: MNPR-101-Zr is in Phase 1 development for cancer imaging, MNPR-101-Lu is in Phase 1a development as a therapy, and MNPR-101-Ac is in preclinical development. The company develops candidates internally and through licensing, and relies on third-party manufacturers for clinical materials. Monopar’s pipeline spans rare disease and cancer rather than reportable business segments. In 2025, it assumed responsibility for ALXN1840 after Alexion transferred the investigational drug application; Monopar plans to pursue regulatory review of the candidate. Its radiopharmaceutical program includes both diagnostic imaging and therapeutic products, with clinical studies enrolling patients with advanced cancers. The filing identifies the company’s website as www.monopartx.com. Its website is www.monopartx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WILMETTE, IL
- Fiscal year end
- December
- CIK
- 1645469
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Monopar Therapeutics — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Monopar Therapeutics’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Monopar Therapeutics and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Monopar Therapeutics's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Monopar Therapeutics's last four quarterly filings that the numbers alone won't show?”